Silence Unveils Preliminary but Encouraging Phase I Data on Cancer Drug

One patient in the study has experienced “remarkable shrinkage” of both target and non-target lesions, according to Silence.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.